{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T16:08:57Z","timestamp":1790352537990,"version":"4.1.0"},"reference-count":105,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.bioorg.2025.108408","type":"journal-article","created":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T15:20:14Z","timestamp":1743002414000},"page":"108408","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Antibody-drug conjugates and radioconjugates targeting carbonic anhydrase IX and XII in hypoxic tumors: Bench to clinical applications"],"prefix":"10.1016","volume":"159","author":[{"given":"Sridhar Goud","family":"Nerella","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahammad Ghouse","family":"Shaik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priti","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Arifuddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qasim","family":"Ullah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudiu T.","family":"Supuran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bioorg.2025.108408_bb0005","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA A Cancer J. Clinicians"},{"issue":"1","key":"10.1016\/j.bioorg.2025.108408_bb0010","article-title":"Shifting tides: the rising tide of early-onset cancers demands attention","volume":"2","author":"Hamilton","year":"2023","journal-title":"BMJ Oncol."},{"issue":"3","key":"10.1016\/j.bioorg.2025.108408_bb0015","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global Cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA A Cancer J Clinicians"},{"issue":"11","key":"10.1016\/j.bioorg.2025.108408_bb0020","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1158\/1541-7786.MCR-23-0411","article-title":"Updating the definition of Cancer","volume":"21","author":"Brown","year":"2023","journal-title":"Mol. Cancer Res."},{"issue":"9","key":"10.1016\/j.bioorg.2025.108408_bb0025","doi-asserted-by":"crossref","first-page":"843","DOI":"10.4155\/fmc-2023-0273","article-title":"Design and synthesis of novel coumarin\u2013benzimidazole hybrids as human galectin-1 inhibitors","volume":"16","author":"Nerella","year":"2024","journal-title":"Future Med. Chem."},{"issue":"19","key":"10.1016\/j.bioorg.2025.108408_bb0030","first-page":"329","article-title":"Antibody-drug conjugates as a targeted therapeutic approach across entities in oncology","volume":"120","author":"Lordick","year":"2023","journal-title":"Dtsch. Arztebl. Int."},{"key":"10.1016\/j.bioorg.2025.108408_bb0035","article-title":"Tumor associated carbonic Anhydrase inhibitors: rational approaches, design strategies, structure activity relationship and mechanistic insights","volume":"10","author":"Nerella","year":"2024","journal-title":"European J. Med. Chem. Rep"},{"key":"10.1016\/j.bioorg.2025.108408_bb0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2018\/9585614","article-title":"Immunotherapies: exploiting the immune system for Cancer treatment","volume":"2018","author":"Koury","year":"2018","journal-title":"J Immunol Res"},{"issue":"1","key":"10.1016\/j.bioorg.2025.108408_bb0045","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41392-024-01856-7","article-title":"Exploring treatment options in Cancer: tumor treatment strategies","volume":"9","author":"Liu","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"issue":"13","key":"10.1016\/j.bioorg.2025.108408_bb0050","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.3390\/cancers16132478","article-title":"Emerging therapeutic strategies to overcome drug resistance in Cancer cells","volume":"16","author":"Garg","year":"2024","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.bioorg.2025.108408_bb0055","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/j.gendis.2022.02.007","article-title":"Cancer chemotherapy and beyond: current status, drug candidates, associated risks and Progress in targeted therapeutics","volume":"10","author":"Anand","year":"2023","journal-title":"Genes & Diseases"},{"issue":"1","key":"10.1016\/j.bioorg.2025.108408_bb0060","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \u201cbiological missile\u201d for targeted Cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.bioorg.2025.108408_bb0065","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/sj.bjc.6600936","article-title":"Diagnostic, prognostic and therapeutic implications of carbonic anhydrases in Cancer","volume":"89","author":"Potter","year":"2003","journal-title":"Br. J. Cancer"},{"issue":"12","key":"10.1016\/j.bioorg.2025.108408_bb0070","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1080\/13543784.2018.1548608","article-title":"Carbonic Anhydrase inhibitors as emerging agents for the treatment and imaging of hypoxic tumors","volume":"27","author":"Supuran","year":"2018","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"8","key":"10.1016\/j.bioorg.2025.108408_bb0075","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1080\/13543776.2022.2083502","article-title":"Anticancer carbonic Anhydrase inhibitors: a patent and literature update 2018-2022","volume":"32","author":"Nerella","year":"2022","journal-title":"Expert Opin. Ther. Pat."},{"issue":"1","key":"10.1016\/j.bioorg.2025.108408_bb0080","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1080\/14756366.2022.2052868","article-title":"Targeting carbonic Anhydrase IX and XII isoforms with small molecule inhibitors and monoclonal antibodies","volume":"37","author":"Kciuk","year":"2022","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108408_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106399","article-title":"PET radiotracers and fluorescent probes for imaging human carbonic Anhydrase IX and XII in hypoxic tumors","volume":"133","author":"Nerella","year":"2023","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.108408_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.104272","article-title":"Synthesis and biological evaluation of some Coumarin hybrids as selective carbonic Anhydrase IX and XII inhibitors","volume":"104","author":"Thacker","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.108408_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112923","article-title":"Recent advances in the medicinal chemistry of carbonic Anhydrase inhibitors","volume":"209","author":"Kumar","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108408_bb0100","article-title":"Synthesis of Chromene-linked Bis-indole derivatives as selective tumor-associated carbonic Anhydrase IX inhibitors","volume":"25","author":"Singh","year":"2024","journal-title":"Anti Cancer Agents Med. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2025.108408_bb0105","doi-asserted-by":"crossref","first-page":"4557","DOI":"10.1038\/s41467-020-18425-5","article-title":"Elucidating the role of metal ions in carbonic Anhydrase catalysis","volume":"11","author":"Kim","year":"2020","journal-title":"Nat. Commun."},{"issue":"14","key":"10.1016\/j.bioorg.2025.108408_bb0110","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1042\/BCJ20160115","article-title":"Structure and function of carbonic anhydrases","volume":"473","author":"Supuran","year":"2016","journal-title":"Biochem. J."},{"issue":"6","key":"10.1016\/j.bioorg.2025.108408_bb0115","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1016\/j.bmc.2012.04.044","article-title":"Structure, Function and applications of carbonic Anhydrase isozymes","volume":"21","author":"Imtaiyaz Hassan","year":"2013","journal-title":"Bioorg. Med. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2025.108408_bb0120","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41392-024-01808-1","article-title":"Drug repurposing for Cancer therapy","volume":"9","author":"Xia","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"issue":"4","key":"10.1016\/j.bioorg.2025.108408_bb0125","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20150089","article-title":"Antibody\u2013drug conjugates as novel anti-cancer chemotherapeutics","volume":"35","author":"Peters","year":"2015","journal-title":"Biosci. Rep."},{"key":"10.1016\/j.bioorg.2025.108408_bb0130","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.1020188","article-title":"Development of radiopharmaceuticals for targeted alpha therapy: where do we stand?","volume":"9","author":"Pallares","year":"2022","journal-title":"Front. Med."},{"issue":"9","key":"10.1016\/j.bioorg.2025.108408_bb0135","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41573-020-0073-9","article-title":"Radiopharmaceutical therapy in Cancer: clinical advances and challenges","volume":"19","author":"Sgouros","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"issue":"2","key":"10.1016\/j.bioorg.2025.108408_bb0140","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.3390\/molecules19022135","article-title":"Radiolabeling strategies for tumor-targeting proteinaceous drugs","volume":"19","author":"Sugiura","year":"2014","journal-title":"Molecules"},{"issue":"6","key":"10.1016\/j.bioorg.2025.108408_bb0145","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1021\/acscentsci.3c00288","article-title":"Covalent proteins as targeted radionuclide therapies enhance antitumor effects","volume":"9","author":"Klauser","year":"2023","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.bioorg.2025.108408_bb0150","series-title":"Mechanism, Regulation, Links to Disease, and Industrial Applications","volume":"75","author":"Anhydrase","year":"2014"},{"issue":"7","key":"10.1016\/j.bioorg.2025.108408_bb0155","doi-asserted-by":"crossref","first-page":"98","DOI":"10.5306\/wjco.v3.i7.98","article-title":"Inhibition of carbonic Anhydrase IX as a novel anticancer mechanism","volume":"3","author":"Supuran","year":"2012","journal-title":"World J. Clinical Oncol."},{"issue":"3","key":"10.1016\/j.bioorg.2025.108408_bb0160","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3390\/metabo7030048","article-title":"Carbonic Anhydrase inhibition and the Management of Hypoxic Tumors","volume":"7","author":"Supuran","year":"2017","journal-title":"Metabolites"},{"issue":"4","key":"10.1016\/j.bioorg.2025.108408_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2024.189120","article-title":"Carbonic Anhydrase IX: an atypical target for innovative therapies in Cancer","volume":"2024","author":"Ronca","year":"1879","journal-title":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"},{"key":"10.1016\/j.bioorg.2025.108408_bb0170","first-page":"4","article-title":"Carbonic Anhydrase IX, a hypoxia-induced catalytic component of the pH regulating machinery in tumors. Frontiers on","author":"Sedlakova","year":"2014","journal-title":"Physiology"},{"issue":"4","key":"10.1016\/j.bioorg.2025.108408_bb0175","doi-asserted-by":"crossref","first-page":"899","DOI":"10.3390\/cancers12040899","article-title":"Transport metabolons and acid\/base balance in tumor cells","volume":"12","author":"Becker","year":"2020","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.bioorg.2025.108408_bb0180","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/s41416-019-0642-z","article-title":"Carbonic Anhydrase IX and acid transport in Cancer","volume":"122","author":"Becker","year":"2020","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.bioorg.2025.108408_bb0185","doi-asserted-by":"crossref","first-page":"339","DOI":"10.3390\/ijms21010339","article-title":"The fundamental role of bicarbonate transporters and associated carbonic Anhydrase enzymes in maintaining ion and pH homeostasis in non-secretory organs","volume":"21","author":"Lee","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.bioorg.2025.108408_bb0190","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0271630","article-title":"Carbonic Anhydrase XII as biomarker and therapeutic target in ovarian carcinomas","volume":"17","author":"Hiepp","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.bioorg.2025.108408_bb0195","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.gene.2017.04.027","article-title":"Carbonic Anhydrase XII functions in health and disease","volume":"623","author":"Waheed","year":"2017","journal-title":"Gene"},{"issue":"9","key":"10.1016\/j.bioorg.2025.108408_bb0200","doi-asserted-by":"crossref","first-page":"6776","DOI":"10.18632\/oncotarget.2882","article-title":"Carbonic Anhydrase XII is a new therapeutic target to overcome Chemoresistance in Cancer cells","volume":"6","author":"Kopecka","year":"2015","journal-title":"Oncotarget"},{"issue":"17","key":"10.1016\/j.bioorg.2025.108408_bb0205","doi-asserted-by":"crossref","first-page":"4322","DOI":"10.7150\/thno.21848","article-title":"Past, present, and future: development of Theranostic agents targeting carbonic Anhydrase IX","volume":"7","author":"Lau","year":"2017","journal-title":"Theranostics"},{"issue":"6","key":"10.1016\/j.bioorg.2025.108408_bb0210","doi-asserted-by":"crossref","first-page":"11402","DOI":"10.3390\/ijms140611402","article-title":"Application of monoclonal antibody G250 recognizing carbonic Anhydrase IX in renal cell carcinoma","volume":"14","author":"Oosterwijk-Wakka","year":"2013","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.bioorg.2025.108408_bb0215","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.3892\/ijo.2014.2658","article-title":"Monoclonal antibody G250 targeting CA IX: binding specificity, internalization and therapeutic effects in a non-renal Cancer model","volume":"45","author":"Zatovicova","year":"2014","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.bioorg.2025.108408_bb0220","first-page":"3","article-title":"Advances in anti-Cancer drug development targeting carbonic Anhydrase IX and XII","volume":"5","author":"Mboge","year":"2015","journal-title":"Anticancer Res."},{"issue":"5","key":"10.1016\/j.bioorg.2025.108408_bb0225","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s00262-011-0980-z","article-title":"Generation and characterization of the first inhibitory antibody targeting tumour-associated carbonic Anhydrase XII","volume":"60","author":"Battke","year":"2011","journal-title":"Cancer Immunol. Immunother."},{"issue":"21","key":"10.1016\/j.bioorg.2025.108408_bb0230","doi-asserted-by":"crossref","first-page":"6494","DOI":"10.1158\/0008-5472.CAN-13-1110","article-title":"Antitumor efficacy of a monoclonal antibody that inhibits the activity of Cancer-associated carbonic Anhydrase XII","volume":"73","author":"Gondi","year":"2013","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.bioorg.2025.108408_bb0235","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3390\/antib9030034","article-title":"Monoclonal antibodies in cancer therapy","volume":"9","author":"Zahavi","year":"2020","journal-title":"Antibodies"},{"issue":"9","key":"10.1016\/j.bioorg.2025.108408_bb0240","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.3390\/biomedicines12092158","article-title":"Revolutionizing Cancer treatment: recent advances in immunotherapy","volume":"12","author":"Ghemrawi","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.bioorg.2025.108408_bb0245","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.drup.2014.11.001","article-title":"Antibody-targeted drugs and drug resistance\u2014challenges and solutions","volume":"18","author":"Shefet-Carasso","year":"2015","journal-title":"Drug Resist. Updat."},{"issue":"20","key":"10.1016\/j.bioorg.2025.108408_bb0250","doi-asserted-by":"crossref","first-page":"4764","DOI":"10.3390\/molecules25204764","article-title":"Antibody\u2013Drug Conjugates for Cancer Therapy","volume":"25","author":"Hafeez","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2025.108408_bb0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2024.118010","article-title":"The journey of antibody-drug conjugates for revolutionizing Cancer therapy: a review","volume":"117","author":"Akram","year":"2025","journal-title":"Bioorg. Med. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2025.108408_bb0260","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1080\/14756366.2021.2004593","article-title":"First studies on tumor associated carbonic anhydrases IX and XII monoclonal antibodies conjugated to small molecule inhibitors","volume":"37","author":"Testa","year":"2022","journal-title":"J. Enzyme Inhib. Med. Chem."},{"issue":"2","key":"10.1016\/j.bioorg.2025.108408_bb0265","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1158\/1535-7163.MCT-11-0523","article-title":"Therapeutic mechanism and efficacy of the antibody\u2013drug conjugate BAY 79\u20134620 targeting human carbonic anhydrase 9","volume":"11","author":"Petrul","year":"2012","journal-title":"Mol. Cancer Ther."},{"issue":"3","key":"10.1016\/j.bioorg.2025.108408_bb0270","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1021\/acs.jmedchem.0c01053","article-title":"Carbon-11: radiochemistry and target-based PET molecular imaging applications in oncology, cardiology, and neurology","volume":"64","author":"Goud","year":"2021","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2025.108408_bb0275","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2967\/jnumed.112.111476","article-title":"An evidence-based review of quantitative SPECT imaging and potential clinical applications","volume":"54","author":"Bailey","year":"2013","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.bioorg.2025.108408_bb0280","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/672094","article-title":"124 Iodine: a longer-life positron emitter isotope\u2014new opportunities in molecular imaging","volume":"2014","author":"Cascini","year":"2014","journal-title":"Biomed. Res. Int."},{"issue":"3","key":"10.1016\/j.bioorg.2025.108408_bb0285","first-page":"423","article-title":"Comparison of image quality of different iodine isotopes (I-123, I-124, and I-131)","volume":"22","author":"Rault","year":"2007","journal-title":"Cancer Biother. Radiopharm."},{"issue":"2","key":"10.1016\/j.bioorg.2025.108408_bb0290","doi-asserted-by":"crossref","first-page":"261","DOI":"10.2214\/AJR.14.12490","article-title":"PET\/CT With124 I-cG250: great potential and some open questions","volume":"203","author":"Khandani","year":"2014","journal-title":"Am. J. Roentgenol."},{"issue":"2","key":"10.1016\/j.bioorg.2025.108408_bb0295","first-page":"155","article-title":"PET Radioimmunoscintigraphy of renal cell Cancer Using89 Zr-labeled cG250 monoclonal antibody in nude rats","volume":"19","author":"Brouwers","year":"2004","journal-title":"Cancer Biother. Radiopharm."},{"issue":"5","key":"10.1016\/j.bioorg.2025.108408_bb0300","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1007\/s00259-013-2679-1","volume":"41","author":"Cheal","year":"2014","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"7","key":"10.1016\/j.bioorg.2025.108408_bb0305","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.2967\/jnumed.109.073189","article-title":"PET of hypoxia with89 Zr-labeled cG250-F(Ab\u2019)2 in head and neck tumors","volume":"51","author":"Hoeben","year":"2010","journal-title":"J. Nucl. Med."},{"issue":"5","key":"10.1016\/j.bioorg.2025.108408_bb0310","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0010857","article-title":"Molecular targeting of carbonic Anhydrase IX in mice with hypoxic HT29 colorectal tumor xenografts","volume":"5","author":"Carlin","year":"2010","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.bioorg.2025.108408_bb0315","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1080\/13543776.2022.2070003","article-title":"Carbon-11 patents (2012\u22122022): synthetic methodologies and novel radiotracers for PET imaging","volume":"32","author":"Nerella","year":"2022","journal-title":"Expert Opin. Ther. Pat."},{"issue":"4","key":"10.1016\/j.bioorg.2025.108408_bb0320","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1080\/13543776.2022.2032649","article-title":"Synthetic methodologies and PET imaging applications of Fluorine-18 radiotracers: a patent review","volume":"32","author":"Nerella","year":"2022","journal-title":"Expert Opin. Ther. Pat."},{"issue":"23","key":"10.1016\/j.bioorg.2025.108408_bb0325","doi-asserted-by":"crossref","first-page":"7017","DOI":"10.1016\/j.bmcl.2011.09.102","article-title":"Radiosynthesis of three [11C]Ureido-substituted Benzenesulfonamides as PET probes for carbonic Anhydrase IX in tumors","volume":"21","author":"Asakawa","year":"2011","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"7","key":"10.1016\/j.bioorg.2025.108408_bb0330","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/0883-2889(88)90056-1","article-title":"The Radiosynthesis of a 11C-labelled carbonic Anhydrase inhibitor\u2014[carbonyl-11C]acetazolamide. International journal of radiation applications and instrumentation. Part a","volume":"39","author":"Le Bars","year":"1988","journal-title":"Appl. Radiat. Isot."},{"issue":"2","key":"10.1016\/j.bioorg.2025.108408_bb0335","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3109\/14756366.2013.773994","article-title":"Synthesis and evaluation of18 F-labeled carbonic Anhydrase IX inhibitors for imaging with positron emission tomography","volume":"29","author":"Pan","year":"2014","journal-title":"J. Enzyme Inhib. Med. Chem."},{"issue":"7","key":"10.1016\/j.bioorg.2025.108408_bb0340","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1097\/COC.0000000000000691","article-title":"A phase 1 study of SLC-0111, a novel inhibitor of carbonic Anhydrase IX, in patients with advanced solid tumors","volume":"43","author":"McDonald","year":"2020","journal-title":"Am. J. Clin. Oncol."},{"issue":"14","key":"10.1016\/j.bioorg.2025.108408_bb0345","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1016\/j.bmcl.2014.05.021","article-title":"Synthesis and evaluation of 18F-labeled tertiary Benzenesulfonamides for imaging carbonic Anhydrase IX expression in Tumours with positron emission tomography","volume":"24","author":"Lau","year":"2014","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"5","key":"10.1016\/j.bioorg.2025.108408_bb0350","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0969-8043(02)00184-7","article-title":"Distribution of 16\u03b1-[18F]Fluoro-Estradiol-3,17\u03b2-Disulfamate in rats, tumour-bearing mice and piglets","volume":"57","author":"Brust","year":"2002","journal-title":"Appl. Radiat. Isot."},{"issue":"6","key":"10.1016\/j.bioorg.2025.108408_bb0355","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S0969-8043(02)00060-X","article-title":"Distribution of Estrone sulfatase in rat brain determined by in vitro autoradiography with 16\u03b1-[18F]Fluoroestradiol-3,17\u03b2-Disulfamate","volume":"56","author":"Rodig","year":"2002","journal-title":"Appl. Radiat. Isot."},{"issue":"1","key":"10.1016\/j.bioorg.2025.108408_bb0360","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1080\/14756366.2017.1308928","article-title":"Design, synthesis and evaluation of18 F-labeled cationic carbonic Anhydrase IX inhibitors for PET imaging","volume":"32","author":"Zhang","year":"2017","journal-title":"J. Enzyme Inhib. Med. Chem."},{"issue":"5","key":"10.1016\/j.bioorg.2025.108408_bb0365","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.bmc.2019.01.014","article-title":"Fluorine-18 click Radiosynthesis and microPET\/CT evaluation of a small peptide-a potential PET probe for carbonic Anhydrase IX","volume":"27","author":"Jia","year":"2019","journal-title":"Bioorg. Med. Chem."},{"issue":"5","key":"10.1016\/j.bioorg.2025.108408_bb0370","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s11307-015-0831-y","article-title":"[18F]VM4-037 MicroPET imaging and biodistribution of two in vivo CAIX-expressing tumor models","volume":"17","author":"Peeters","year":"2015","journal-title":"Mol. Imaging Biol."},{"issue":"5","key":"10.1016\/j.bioorg.2025.108408_bb0375","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s11307-014-0730-7","article-title":"Biodistribution and radiation dosimetry of the carbonic Anhydrase IX imaging agent [18 F]VM4-037 determined from PET\/CT scans in healthy volunteers","volume":"16","author":"Doss","year":"2014","journal-title":"Mol. Imaging Biol."},{"issue":"5","key":"10.1016\/j.bioorg.2025.108408_bb0380","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.bmcl.2018.01.060","article-title":"Acetazolamide-Based [ 18 F]-PET Tracer: In Vivo Validation of Carbonic Anhydrase IX as a Sole Target for Imaging of CA-IX Expressing Hypoxic Solid Tumors","volume":"vol. 28","author":"More","year":"2018","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"9","key":"10.1016\/j.bioorg.2025.108408_bb0385","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.2967\/jnumed.114.153288","article-title":"Trimeric Radiofluorinated sulfonamide derivatives to achieve in vivo selectivity for carbonic Anhydrase IX\u2013targeted PET imaging","volume":"56","author":"Lau","year":"2015","journal-title":"J. Nucl. Med."},{"issue":"3","key":"10.1016\/j.bioorg.2025.108408_bb0390","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1021\/acs.molpharmaceut.5b00934","article-title":"PET imaging of carbonic Anhydrase IX expression of HT-29 tumor xenograft mice with68 Ga-labeled Benzenesulfonamides","volume":"13","author":"Lau","year":"2016","journal-title":"Mol. Pharm."},{"issue":"13","key":"10.1016\/j.bioorg.2025.108408_bb0395","doi-asserted-by":"crossref","first-page":"6431","DOI":"10.1021\/acs.jmedchem.6b00623","article-title":"Synthesis and in vivo biological evaluation of68 Ga-labeled carbonic Anhydrase IX targeting small molecules for positron emission tomography","volume":"59","author":"Sneddon","year":"2016","journal-title":"J. Med. Chem."},{"issue":"32","key":"10.1016\/j.bioorg.2025.108408_bb0400","doi-asserted-by":"crossref","first-page":"33733","DOI":"10.18632\/oncotarget.5254","article-title":"Imaging of carbonic Anhydrase IX with an 111In-labeled dual-motif inhibitor","volume":"6","author":"Yang","year":"2015","journal-title":"Oncotarget"},{"issue":"35","key":"10.1016\/j.bioorg.2025.108408_bb0405","doi-asserted-by":"crossref","first-page":"56471","DOI":"10.18632\/oncotarget.10602","article-title":"[64Cu]XYIMSR-06: a dual-motif CAIX ligand for PET imaging of clear cell renal cell carcinoma","volume":"7","author":"Minn","year":"2016","journal-title":"Oncotarget"},{"issue":"11","key":"10.1016\/j.bioorg.2025.108408_bb0410","doi-asserted-by":"crossref","first-page":"4859","DOI":"10.1039\/C4DT03206C","article-title":"Synthesis of sulfonamide conjugates of cu (ii), Ga (iii), in (iii), re (v) and Zn (ii) complexes: carbonic Anhydrase inhibition studies and cellular imaging investigations","volume":"44","author":"Dilworth","year":"2015","journal-title":"Dalton Trans."},{"issue":"4","key":"10.1016\/j.bioorg.2025.108408_bb0415","first-page":"379","article-title":"Copper-64 radiopharmaceuticals for PET imaging of Cancer: advances in preclinical and clinical research","volume":"24","author":"Anderson","year":"2009","journal-title":"Cancer Biother. Radiopharm."},{"issue":"6","key":"10.1016\/j.bioorg.2025.108408_bb0420","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1021\/acs.molpharmaceut.0c00180","article-title":"In search of advanced tumor diagnostics and treatment: achievements and perspectives of carbonic Anhydrase IX targeted delivery","volume":"17","author":"Janoniene","year":"2020","journal-title":"Mol. Pharm."},{"issue":"2","key":"10.1016\/j.bioorg.2025.108408_bb0425","first-page":"327","article-title":"Optimization of Radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re","volume":"45","author":"Brouwers","year":"2004","journal-title":"J. Nucl. Med."},{"issue":"10 Pt 2","key":"10.1016\/j.bioorg.2025.108408_bb0430","first-page":"3953S","article-title":"Targeting of metastatic renal cell carcinoma with the chimeric monoclonal antibody G250 labeled with (131)I or (111)in: an Intrapatient comparison","volume":"9","author":"Brouwers","year":"2003","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.bioorg.2025.108408_bb0435","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s002620050371","article-title":"Advantage of residualizing radiolabels for an internalizing antibody against the B-cell lymphoma antigen, CD22","volume":"44","author":"Sharkey","year":"1997","journal-title":"Cancer Immunol. Immunother."},{"issue":"11","key":"10.1016\/j.bioorg.2025.108408_bb0440","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.7150\/thno.20982","article-title":"Cancer Radiotheranostics targeting carbonic Anhydrase-IX with111 in- and90 Y-labeled Ureidosulfonamide scaffold for SPECT imaging and radionuclide-based therapy","volume":"8","author":"Iikuni","year":"2018","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.bioorg.2025.108408_bb0445","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00345-010-0570-2","article-title":"A clinical phase I\/II trial with the monoclonal antibody cG250 (RENCAREX\u00ae) and interferon-alpha-2a in metastatic renal cell carcinoma patients","volume":"29","author":"Siebels","year":"2011","journal-title":"World. J. Urol."},{"issue":"2","key":"10.1016\/j.bioorg.2025.108408_bb0450","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.neo.2014.12.011","article-title":"Successful combination of Sunitinib and Girentuximab in two renal cell carcinoma animal models: a rationale for combination treatment of patients with advanced RCC","volume":"17","author":"Oosterwijk-Wakka","year":"2015","journal-title":"Neoplasia"},{"issue":"7","key":"10.1016\/j.bioorg.2025.108408_bb0455","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1001\/jamaoncol.2016.4419","article-title":"Adjuvant weekly Girentuximab following nephrectomy for high-risk renal cell carcinoma: the ARISER randomized clinical trial","volume":"3","author":"Chamie","year":"2017","journal-title":"JAMA Oncol."},{"issue":"5","key":"10.1016\/j.bioorg.2025.108408_bb0460","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.eururo.2015.11.033","article-title":"Phase 2 Study of Lutetium 177\u2013Labeled Anti\u2013Carbonic Anhydrase IX Monoclonal Antibody Girentuximab in Patients with Advanced Renal Cell Carcinoma","volume":"69","author":"Muselaers","year":"2016","journal-title":"Eur. Urol."},{"issue":"3","key":"10.1016\/j.bioorg.2025.108408_bb0465","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1158\/1078-0432.CCR-22-0921","article-title":"[89Zr]Zr-DFO-Girentuximab and [18F]FDG PET\/CT to Predict Watchful Waiting Duration in Patients with Metastatic Clear-Cell Renal Cell Carcinoma","volume":"29","author":"Verhoeff","year":"2023","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.bioorg.2025.108408_bb0470","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/ijc.11142","article-title":"Biodistribution and pharmacokinetics of125 I-labeled monoclonal antibody M75 specific for carbonic Anhydrase IX, an intrinsic marker of hypoxia, in nude mice Xenografted with human colorectal carcinoma","volume":"105","author":"Chrastina","year":"2003","journal-title":"Int. J. Cancer"},{"issue":"47","key":"10.1016\/j.bioorg.2025.108408_bb0475","doi-asserted-by":"crossref","first-page":"44497","DOI":"10.1021\/acsomega.3c01934","article-title":"Selective tumor hypoxia targeting using M75 antibody conjugated Photothermally active MoO x nanoparticles","volume":"8","author":"Annu\u0161ov\u00e1","year":"2023","journal-title":"ACS Omega"},{"issue":"8","key":"10.1016\/j.bioorg.2025.108408_bb0480","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.7150\/thno.23335","article-title":"Tumor-targeted dual-modality imaging to improve intraoperative visualization of clear cell renal cell carcinoma: a first in man study","volume":"8","author":"Hekman","year":"2018","journal-title":"Theranostics"},{"issue":"3","key":"10.1016\/j.bioorg.2025.108408_bb0485","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.eururo.2018.04.026","article-title":"Positron emission tomography\/computed tomography with 89Zr-Girentuximab can aid in diagnostic dilemmas of clear cell renal cell carcinoma suspicion","volume":"74","author":"Hekman","year":"2018","journal-title":"Eur. Urol."},{"issue":"9","key":"10.1016\/j.bioorg.2025.108408_bb0490","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1007\/s00259-019-04358-9","article-title":"Lesion detection by [89Zr]Zr-DFO-Girentuximab and [18F]FDG-PET\/CT in patients with newly diagnosed metastatic renal cell carcinoma","volume":"46","author":"Verhoeff","year":"2019","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"4","key":"10.1016\/j.bioorg.2025.108408_bb0495","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1200\/JCO.1993.11.4.738","article-title":"Antibody localization in human renal cell carcinoma: a phase I study of monoclonal antibody G250","volume":"11","author":"Oosterwijk","year":"1993","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.bioorg.2025.108408_bb0500","first-page":"2729","article-title":"Phase I\/II Radioimmunotherapy trial with Iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma","volume":"4","author":"Divgi","year":"1998","journal-title":"Clin. Cancer Res."},{"issue":"27","key":"10.1016\/j.bioorg.2025.108408_bb0505","doi-asserted-by":"crossref","first-page":"6540","DOI":"10.1200\/JCO.2005.07.732","article-title":"Lack of efficacy of two consecutive treatments of Radioimmunotherapy with131 I-cG250 in patients With metastasized clear cell renal cell carcinoma","volume":"23","author":"Brouwers","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.bioorg.2025.108408_bb0510","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.eururo.2012.08.024","article-title":"Phase 1 Radioimmunotherapy study with lutetium 177\u2013labeled anti-carbonic Anhydrase IX monoclonal antibody Girentuximab in patients with advanced renal cell carcinoma","volume":"64","author":"Stillebroer","year":"2013","journal-title":"Eur. Urol."},{"issue":"6_suppl","key":"10.1016\/j.bioorg.2025.108408_bb0515","doi-asserted-by":"crossref","first-page":"TPS752","DOI":"10.1200\/JCO.2023.41.6_suppl.TPS752","article-title":"STARLITE 2: Phase 2 Study of Nivolumab plus177 Lutetium-Labeled Anti\u2013Carbonic Anhydrase IX (CAIX) Monoclonal Antibody Girentuximab (177 Lu-Girentuximab) in Patients (Pts) with Advanced Clear Cell Renal Cell Carcinoma (ccRCC)","volume":"41","author":"Feldman","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.bioorg.2025.108408_bb0520","doi-asserted-by":"crossref","first-page":"570","DOI":"10.3390\/ph15050570","article-title":"Carbonic Anhydrase IX-targeted \u03b1-radionuclide therapy with 225Ac inhibits tumor growth in a renal cell carcinoma model","volume":"15","author":"Merkx","year":"2022","journal-title":"Pharmaceuticals"},{"issue":"5","key":"10.1016\/j.bioorg.2025.108408_bb0525","doi-asserted-by":"crossref","first-page":"740","DOI":"10.2967\/jnumed.123.267175","article-title":"First-in-human safety, imaging, and dosimetry of a carbonic Anhydrase IX\u2013targeting peptide, [68 Ga]Ga-DPI-4452, in patients with clear cell renal cell carcinoma","volume":"65","author":"Hofman","year":"2024","journal-title":"J. Nucl. Med."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825002883?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825002883?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T20:15:40Z","timestamp":1745871340000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206825002883"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":105,"alternative-id":["S0045206825002883"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.108408","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antibody-drug conjugates and radioconjugates targeting carbonic anhydrase IX and XII in hypoxic tumors: Bench to clinical applications","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.108408","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108408"}}